A phase I dose escalation study of ad GV.EGR.TNF.11D (TNFeradeTMM Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 769-776

  Seiwert, T Y ^a   Darg, T ^a   Haraf, D ^a   Blair, E A ^a   Stenson, K ^a   Cohen, E E W ^a   Salama, J K ^a   Villaflor, V ^a   Witt, M E ^a   Lingen, M W ^a   Weichselbaum, R R ^a   Vokes, E E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Chemoradiation; Gene therapy; Head and neck cancer; Recurrent disease; Translational research

Indexed keywords

ADENOVIRUS VECTOR; ADGV EGR TNF 11D; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GENE THERAPY AGENT; HYDROXYUREA; TNFERADE BIOLOGIC; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RECEPTOR;

ABSCESS; ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BLEEDING; CANCER RADIOTHERAPY; CELLULITIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DERMATITIS; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; FEVER; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYPONATREMIA; HYPOXIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INJECTION SITE PAIN; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MENTAL HEALTH; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RESPIRATORY ALKALOSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DNA; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; GENETIC THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RETREATMENT; TREATMENT OUTCOME;

EID: 84874578991     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds523     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-236.
2. Salama JK, Vokes EE, Chmura SJ et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64(2): 382-391.
3. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116-1127.
4. Spencer SA, Harris J, Wheeler RH et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51(5): 1299-1304.
5. Stevens KR, Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994; 29(4): 687-698.
6. Vokes EE, Panje WR, Schilsky RL et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989; 7(6): 761-768.
7. Brockstein B, Haraf DJ, Stenson K et al. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol 2000; 11(6): 721-728.
8. Brockstein B, Haraf DJ, Stenson K et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998; 16(2): 735-744.
9. Vokes EE, Haraf DJ, Mick R et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994; 12(11): 2351-2359.
10. Milano MT, Vokes EE, Salama JK et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 2005; 61(4): 1096-1106.
11. Haraf DJ, Weichselbaum RR, Vokes EE. Reirradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 1996; 7(9): 913-918.
12. Salama JK, Haraf DJ, Stenson K et al. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J 2005; 11(2): 140-146.
13. De Crevoisier R, Bourhis J, Domenge C et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998; 16(11): 3556-3562.
14. De Crevoisier R, Domenge C, Wibault P et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001; 91(11): 2071-2076.
15. Spencer SA, Wheeler RH, Peters GE et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999; 22(1): 1-5.
16. Langer CJ, Harris J, Horwitz EM et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of radiation therapy oncology group protocol 9911. J Clin Oncol 2007; 25(30): 4800-4805.
17. Janot F, de Raucourt D, Benhamou E et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26(34): 5518-23.
18. Hallahan DE, Mauceri HJ, Seung LP et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1(8): 786-791.
19. Mauceri HJ, Beckett MA, Liang H et al. Translational strategies exploiting TNFalpha that sensitize tumors to radiation therapy. Cancer Gene Ther 2009; 16(4): 373-381.
20. McLoughlin JM, McCarty TM, Cunningham C et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up. Ann Surg Oncol 2005; 12(10): 825-830.
21. Kufe D, Weichselbaum R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2003; 2(4): 326-329.
22. Weichselbaum RR, Kufe D. Translation of the radioand chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther 2009; 16(8): 609-619.
23. Mundt AJ, Vijayakumar S, Nemunaitis J et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004; 10(17): 5747-5753.
24. Senzer N, Mani S, Rosemurgy A et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004; 22(4): 592-601.
25. Sharma A, Mani S, Hanna N et al. Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther 2001; 12(9): 1109-1131.
26. Calzascia T, Pellegrini M, Hall H et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007; 117(12): 3833-3845.
27. Slattery ML, Lundgreen A, Bondurant KL et al. Tumor necrosis factor-related genes and colon and rectal cancer. Int J Mol Epidemiol Genet. 2011; 2(4): 328-338.
28. Meng Y, Mauceri HJ, Khodarev NN et al. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther 2010; 18(5): 912-920.
29. Vokes EE, Beckett M, Karrison T et al. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology 1992; 49(6): 454-460.
30. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med 1993; 328(3): 184-194.
31. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990; 8(5): 911-934.
32. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989; 45(3): 925-937.
33. Seiwert TY, Haraf DJ, Cohen EEW et al. Phase I study of bevacizumab added to fluorouraciland hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008; 26(10): 1732-1741.
34. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
35. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18(6): 695-706.
36. Jenks S. Gene therapy death-'everyone has to share in the guilt'. J Natl Cancer Inst 2000; 92(2): 98-100.
37. Gene therapy shown to destroy leukemia tumors, Reuters 2011. http://www. reuters.com/article/2011/08/10/us-leukemia-genetherapyidUSTRE7795NT20110810 (10 October 2012, date last accessed).
38. Aiuti A, Cattaneo F, Galimberti S et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360(5): 447-458.
39. Hacein-Bey-Abina S, Hauer J, Lim A et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363(4): 355-364.
40. Nathwani AC, Tuddenham EGD, Rangarajan S et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365(25): 2357-2365.
41. Gaspar HB, Cooray S, Gilmour KC et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3(97): 97ra80.
42. Gaspar HB, Cooray S, Gilmour KC et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3(97): 97ra79.
43. Shaw KL, Kohn DB. A tale of two SCIDs. Sci Transl Med 2011; 3(97): 97ps36.
44. Mezhir JJ, Smith KD, Posner MC et al. Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther 2006; 13(1): 1-6.
45. Murugesan SR, King CR, Osborn R et al. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 2009; 16(11): 841-847.
46. Hallahan DE, Beckett MA, Kufe D et al. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 1990; 19: 69-74.
47. Meng Y, Beckett MA, Liang H et al. Blockade of tumor necrosis factor signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 2010; 70: 1534-1543.
48. Park EJ, Lee JH, Yu GY et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.